Specialized Solid Form Screening Techniques

Solid form screening is an integral part of many development plans at various companies and includes polymorph, salt, cocrystal, amorphous, and amorphous dispersion screens. There are a number of traditional solvent- and nonsolvent-based methods that are employed for these screens. Over time, specialized screens have been developed to deal with difficult molecules and situations or to push the limits of traditional experiments. This contribution outlines a variety of specialized screening approaches for polymorphs, salts, cocrystals, and amorphous dispersions. Many techniques are amenable to laboratory equipment and can be incorporated with minimal start-up time, while others are very specific and will need specialized equipment and/or expertise.

[1]  Patrick Marroum,et al.  Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus , 2012 .

[2]  J. Ketolainen,et al.  Computational approach for fast screening of small molecular candidates to inhibit crystallization in amorphous drugs. , 2012, Molecular pharmaceutics.

[3]  H. Ohno,et al.  Ionic liquid/water mixtures: from hostility to conciliation. , 2012, Chemical communications.

[4]  Claire S. Adjiman,et al.  Towards crystal structure prediction of complex organic compounds – a report on the fifth blind test , 2011, Acta crystallographica. Section B, Structural science.

[5]  L. Casettari,et al.  Poloxamer Thermogel Systems as Medium for Crystallization , 2011, Pharmaceutical Research.

[6]  Sarah L Price,et al.  Computational prediction of salt and cocrystal structures--does a proton position matter? , 2011, International journal of pharmaceutics.

[7]  S. R. Bysouth,et al.  Cocrystallization via planetary milling: enhancing throughput of solid-state screening methods. , 2011, International journal of pharmaceutics.

[8]  Jia Liu,et al.  Medium-throughput hydrate screening using the Crystal 16™ , 2011, Pharmaceutical development and technology.

[9]  Beatrice Perissutti,et al.  Enhanced Oral Bioavailability of Vinpocetine Through Mechanochemical Salt Formation: Physico-Chemical Characterization and In Vivo Studies , 2011, Pharmaceutical Research.

[10]  D. Ende,et al.  Chemical engineering in the pharmaceutical industry : R&D to manufacturing , 2010 .

[11]  S. Byrn,et al.  A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. , 2010, Journal of pharmaceutical sciences.

[12]  Keith R Horspool,et al.  Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.

[13]  J. Rantanen,et al.  Towards effective solid form screening. , 2010, Journal of pharmaceutical sciences.

[14]  Woo-Sik Kim,et al.  Application of Ionic Liquid to Polymorphic Design of Pharmaceutical Ingredients , 2010 .

[15]  Henrique A. Matos,et al.  Screening for pharmaceutical cocrystals using the supercritical fluid enhanced atomization process , 2010 .

[16]  J. McCabe Application of design of experiment (DOE) to polymorph screening and subsequent data analysis , 2010 .

[17]  Jan Van Humbeeck,et al.  Influence of Preparation Methods on Solid State Supersaturation of Amorphous Solid Dispersions: A Case Study with Itraconazole and Eudragit E100 , 2010, Pharmaceutical Research.

[18]  D. Macfarlane,et al.  Crystalline vs. Ionic Liquid Salt Forms of Active Pharmaceutical Ingredients: A Position Paper , 2010, Pharmaceutical Research.

[19]  Bing-Shiou Yang,et al.  A Practical Solid Form Screen Approach To Identify a Pharmaceutical Glutaric Acid Cocrystal for Development , 2009 .

[20]  Luis Padrela,et al.  Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  P. Karamertzanis,et al.  Salt or Cocrystal? A New Series of Crystal Structures Formed from Simple Pyridines and Carboxylic Acids , 2009 .

[22]  I. Miroshnyk,et al.  Pharmaceutical co-crystals–an opportunity for drug product enhancement , 2009, Expert opinion on drug delivery.

[23]  Richard W. Duerst,et al.  Cocrystals of Caffeine and Hydroxybenzoic Acids Composed of Multiple Supramolecular Heterosynthons: Screening via Solution-Mediated Phase Transformation and Structural Characterization , 2009 .

[24]  S. Childs,et al.  The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome , 2009 .

[25]  D. Macfarlane,et al.  Exploring an Anti-Crystal Engineering Approach to the Preparation of Pharmaceutically Active Ionic Liquids , 2009 .

[26]  David R. Weyna,et al.  Synthesis and Structural Characterization of Cocrystals and Pharmaceutical Cocrystals: Mechanochemistry vs Slow Evaporation from Solution , 2009 .

[27]  P. Karamertzanis,et al.  Can the Formation of Pharmaceutical Cocrystals Be Computationally Predicted? I. Comparison of Lattice Energies , 2009 .

[28]  Jukka Rantanen,et al.  Solid form screening--a review. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  Yong Cui,et al.  Evaluation of hydrate-screening methods. , 2008, Journal of pharmaceutical sciences.

[30]  N. Rodríguez-Hornedo,et al.  Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine , 2008 .

[31]  K. Terada,et al.  Cocrystal Screening of Stanolone and Mestanolone Using Slurry Crystallization , 2008 .

[32]  Wen-ting Cheng,et al.  Famotidine polymorphic transformation in the grinding process significantly depends on environmental humidity or water content. , 2008, International journal of pharmaceutics.

[33]  Enxian Lu,et al.  Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. , 2008, Journal of pharmaceutical sciences.

[34]  Raj Suryanarayanan,et al.  A rapid thermal method for cocrystal screening , 2008 .

[35]  C. C. Seaton,et al.  Applying Hot-Stage Microscopy to Co-Crystal Screening: A Study of Nicotinamide with Seven Active Pharmaceutical Ingredients , 2008 .

[36]  M. Sherry Ku,et al.  Use of the Biopharmaceutical Classification System in Early Drug Development , 2008, The AAPS Journal.

[37]  Gary Eichenbaum,et al.  Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing. , 2008, International journal of pharmaceutics.

[38]  Shayne C. Gad,et al.  Preclinical Development Handbook , 2008 .

[39]  Lokesh Kumar,et al.  An overview of automated systems relevant in pharmaceutical salt screening. , 2007, Drug discovery today.

[40]  A. Matzger,et al.  New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation. , 2007, Journal of pharmaceutical sciences.

[41]  G. P. Stahly Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .

[42]  David R. Weyna,et al.  Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor. , 2007, Molecular pharmaceutics.

[43]  T. Friščić,et al.  Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. , 2007, Molecular pharmaceutics.

[44]  Ron J Roberts,et al.  Structure, solubility, screening, and synthesis of molecular salts. , 2007, Journal of pharmaceutical sciences.

[45]  Geoff G. Z. Zhang,et al.  Efficient co-crystal screening using solution-mediated phase transformation. , 2007, Journal of pharmaceutical sciences.

[46]  W. Jones,et al.  Screening for crystalline salts via mechanochemistry. , 2006, Chemical communications.

[47]  William Jones,et al.  Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement , 2006 .

[48]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[49]  P. Dyson,et al.  1H, 19F-HOESY and PGSE diffusion studies on ionic liquids: The effect of co-solvent on structure , 2006 .

[50]  Sarah J. Nehm,et al.  Reaction crystallization of pharmaceutical molecular complexes. , 2006, Molecular pharmaceutics.

[51]  Sarah J. Nehm,et al.  Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation , 2006 .

[52]  Alfred Y Lee,et al.  Factors Affecting the Polymorphic Outcome of Glycine Crystals Constrained on Patterned Substrates , 2006 .

[53]  Alfred Y Lee,et al.  Influence of Impurities on the Solution-Mediated Phase Transformation of an Active Pharmaceutical Ingredient , 2005 .

[54]  A. Matzger,et al.  Crystalline polymorph selection and discovery with polymer heteronuclei. , 2005, Journal of the American Chemical Society.

[55]  David J W Grant,et al.  Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.

[56]  A. Goho Tricky business: The crystal form of a drug can be the secret to its success , 2004 .

[57]  Åke C. Rasmuson,et al.  Influence of Additives on Nucleation of Vanillin: Experiments and Introductory Molecular Simulations , 2004 .

[58]  William Jones,et al.  Solvent-drop grinding: green polymorph control of cocrystallisation. , 2004, Chemical communications.

[59]  W. Curatolo,et al.  Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.

[60]  Geoff G. Z. Zhang,et al.  Phase transformation considerations during process development and manufacture of solid oral dosage forms. , 2004, Advanced drug delivery reviews.

[61]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[62]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[63]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[64]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[65]  D. Grant,et al.  Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.

[66]  B. Shekunov,et al.  Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS). , 2001, Journal of pharmaceutical sciences.

[67]  W. Beckmann,et al.  Crystallisation of the Stable Polymorph of Hydroxytriendione: Seeding Process and Effects of Purity , 2001 .

[68]  Michael B. Hursthouse,et al.  Over one hundred solvates of sulfathiazole , 2001 .

[69]  C. A. Mitchell,et al.  Crystallization and Polymorphism of Conformationally Flexible Molecules: Problems, Patterns, and Strategies , 2000 .

[70]  C. Rustichelli,et al.  Solid-state study of polymorphic drugs: carbamazepine. , 2000, Journal of pharmaceutical and biomedical analysis.

[71]  S. Chemburkar,et al.  Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .

[72]  H. Brittain Polymorphism in Pharmaceutical Solids , 1999 .

[73]  G. Desiraju,et al.  Pseudopolymorphism: occurrences of hydrogen bonding organic solvents in molecular crystals , 1999 .

[74]  Y. Marcus The properties of solvents , 1998 .

[75]  Suryanarayanan,et al.  Applications of pressure differential scanning calorimetry in the study of pharmaceutical hydrates. I. Carbamazepine dihydrate. , 1997, International journal of pharmaceutics.

[76]  A. Dzyabchenko,et al.  X-ray characterization of the triclinic polymorph of carbamazepine. , 1997, Journal of pharmaceutical sciences.

[77]  P. York,et al.  Characterization of dihydrates prepared from carbamazepine polymorphs. , 1996, Journal of pharmaceutical sciences.

[78]  D. Grant,et al.  Research paperInfluence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Theophylline , 1996 .

[79]  M. C. Etter Encoding and decoding hydrogen-bond patterns of organic compounds , 1990 .

[80]  F. Lefaucheux,et al.  Crystal growth in gels: Principle and applications , 1988 .

[81]  F. Krahn,et al.  Relations between several polymorphic forms and the dihydrate of carbamazepine. , 1987, Pharmaceutica acta Helvetiae.

[82]  S. Suib Crystal growth in gels , 1985 .

[83]  Donald C. Monkhouse,et al.  Review ArticlePharmaceutical Salts , 1977 .

[84]  W. Powrie,et al.  Gas hydrates in aqueous-organic systems. 3. Hydrate formation in polyacrylamide gel. , 1966, Cryobiology.